Blue Earth Therapeutics Ltd Expands Partnership with Seibersdorf Labor GmbH to Include Manufacturing of Therapeutic Radiopharmaceutical 225Ac-rhPSMA-10.1
Tuesday, August 13, 2024
Blue Earth Therapeutics Ltd, a Bracco company and a rising leader in innovative next-generation therapeutic radiopharmaceuticals, has announced the expansion of its manufacturing agreements with Seibersdorf Labor GmbH. This partnership now includes the production of Blue Earth Therapeutics’ investigational 225Ac-based radioligand therapy. The expanded agreement ensures a future supply for clinical trial sites in the UK, EU, and US. The investigational radiopharmaceutical, 225Ac-rhPSMA-10.1, is a radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic and marks the second candidate in Blue Earth Therapeutics’ oncology development program.
“We are very pleased to include the manufacturing of our 225Ac-based investigational product in our partnership with Seibersdorf Labor,” said David E. Gauden, DPhil., CEO of Blue Earth Therapeutics Ltd. “This collaboration will ensure the supply of high-purity, stable doses for clinical trial sites in London and potentially other regions. Seibersdorf has been an exceptional partner, and we look forward to continuing our collaboration on future projects.”
Dr. Markus Neumann, Managing Director of Seibersdorf Labor GmbH, added, “This is our first project utilizing the 225Ac radioisotope, and we have developed specialized infrastructure and services to support it. We are excited to expand our expertise in 225Ac and to collaborate with Blue Earth Therapeutics on this new agent, providing doses for patients in clinical trials. Blue Earth Therapeutics has been a highly supportive partner, and we are proud to be part of their network.”
Source: blueearththerapeutics.com
